Methylation of the suppressor of Cytokine Signaling 1 Gene (SOCS1) in Philadelphia-negative myeloproliferative neoplasms.

OBJECTIVE Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway activation is initiated by mutations in the JAK2 gene. This activation is in turn, a vital pathogenetic mechanism in myeloproliferative neoplasms (MPNs). However, several factors affect the pathogenesis of MPNs other than the JAK2 gene mutations, such as the downregulation of cytokine signaling (SOCS) proteins, which are potent inhibitors of the JAK/STAT pathway. Therefore, we hypothesized that the regulation of SOCS protein system might be a possible pathogenetic mechanism of MPNs through activating the JAK/STAT pathway. PATIENTS AND METHODS Our study aimed to investigate the status of the Suppressors of cytokine signaling 1 (SOCS1) in 125 MPNs specimens at the level of mutated points. The acquired mutations, aberrant expression, and/or CpG island hypermethylation of SOCS1 were analyzed among Philadelphia-negative myeloproliferative neoplasm patients. RESULTS SOCS1 was identified in 20.0% of all patients with Philadelphia-negative myeloproliferative neoplasm. At the diagnosis, the prevalence of methylation was 41.0% for Polycythaemia Vera (PV), 27.7% for Essential Thrombocythaemia (ET), and 6.6% for Primary Myelofibrosis (PMF). The methylation was not detected in 20 healthy adult people. A significant association was found between disease groups (p=.077). The presence of methylated SOCS1 was found to be significantly correlated with age (p=.005), total RBCs count (p=.019), hemoglobin (Hb) concentration (p=.002), and Hematopoietic cell transplant (HCT) (p=.007) in PV patients. However, the presence of methylated SOCS1 was found to be significantly associated with age (p=.012), total RBCs count (p=.022), Hb concentration (p=.024), HCT (p=.033), and platelets count (p=.037) in ET patients. Moreover, the presence of methylated SOCS1 was significantly associated with Hb concentration (p=.046) and HCT (p=.040) in PMF patients. CONCLUSIONS We concluded that the activation of the JAK/STAT signaling pathway in alternative or with JAK2 mutations leads to SOCS1 hypermethylation, which could represent a potential therapeutic target.

[1]  Hubert Vesselle,et al.  DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. , 2010, Lung cancer.

[2]  F. Passamonti,et al.  Clinical relevance of JAK2 (V617F) mutant allele burden , 2009, Haematologica.

[3]  P. Campbell,et al.  Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders , 2008, Haematologica.

[4]  H. Brenner,et al.  Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study , 2008, PloS one.

[5]  P. Campbell,et al.  MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. , 2008, Blood.

[6]  P. Laird,et al.  Widespread Epigenetic Abnormalities Suggest a Broad DNA Methylation Erasure Defect in Abnormal Human Sperm , 2007, PloS one.

[7]  M. Vieth,et al.  Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett’s adenocarcinoma , 2007, Gut.

[8]  J. Herman,et al.  Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders , 2007, Leukemia.

[9]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[10]  R. Hoffman,et al.  Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. , 2006, Blood.

[11]  P. Campbell,et al.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.

[12]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[13]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[14]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[15]  I. Weissman,et al.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[17]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[18]  F. Sommerer,et al.  SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition , 2005, Oncogene.

[19]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[20]  Kenichi Matsubara,et al.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.

[21]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[22]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[23]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[24]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[25]  J. Reilly,et al.  Aberrant methylation of the negative regulators RASSFIA, SHP‐1 and SOCS‐1 in myelodysplastic syndromes and acute myeloid leukaemia , 2005, British journal of haematology.

[26]  Y. Kwong,et al.  SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. , 2004, Blood.

[27]  Biao He,et al.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Jan-Gowth Chang,et al.  Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia , 2003, British journal of haematology.

[29]  W. Alexander,et al.  The suppressors of cytokine signalling (SOCS) , 2001, Cellular and Molecular Life Sciences CMLS.

[30]  D. Hilton,et al.  SOCS Proteins: Negative Regulators of Cytokine Signaling , 2001, Stem cells.

[31]  A. Yoshimura,et al.  CIS3/SOCS-3 Suppresses Erythropoietin (EPO) Signaling by Binding the EPO Receptor and JAK2* , 2000, The Journal of Biological Chemistry.

[32]  Y. Miyakawa,et al.  Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. , 2000, Blood.

[33]  H. Pendeville,et al.  SOCS3 Is Essential in the Regulation of Fetal Liver Erythropoiesis , 1999, Cell.

[34]  A. Yoshimura,et al.  SOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality , 1999, Cell.

[35]  A. Yoshimura,et al.  The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop , 1999, The EMBO journal.

[36]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[37]  A. Cumano,et al.  Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.

[38]  K. Takenaka,et al.  Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F , 2008, Leukemia.

[39]  R. Hoffman,et al.  Biology and treatment of primary myelofibrosis. , 2007, Hematology. American Society of Hematology. Education Program.

[40]  P. Campbell,et al.  An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation. , 2006, Haematologica.

[41]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[42]  W. Vainchenker,et al.  A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. , 2005, Hematology. American Society of Hematology. Education Program.